Does the Addition of Abiraterone to Castration Affect the Reduction in Bone Mineral Density?
Androgen deprivation therapy
bone microenvironment
bone mineral density
micro-computed tomography
osteoblasts
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
21
08
2020
revised:
10
09
2020
accepted:
14
09
2020
entrez:
4
11
2020
pubmed:
5
11
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
The in vivo effect of abiraterone on bone mineral density (BMD) in addition to androgen deprivation therapy was examined using a murine model. The mice were separated into the following groups: control, abiraterone, castration, and castration+abiraterone. The percentage change in the ratio of bone to tissue volume (BV/TV), number of osteoblasts and osteoclasts, and the serum level of bone markers were compared on day 21. The BV/TV ratio of the abiraterone, castration, and castration+abiraterone groups was lower than that of the control group. However, the change in the BV/TV ratio in the castration+abiraterone group was not significantly different from that in the castration group. There was no significant difference in the serum TRAP5b level and the number of osteoclasts and osteoblasts between the castration+abiraterone and the castration groups. The addition of abiraterone to castration did not affect BMD in the murine model.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
The in vivo effect of abiraterone on bone mineral density (BMD) in addition to androgen deprivation therapy was examined using a murine model.
MATERIALS AND METHODS
METHODS
The mice were separated into the following groups: control, abiraterone, castration, and castration+abiraterone. The percentage change in the ratio of bone to tissue volume (BV/TV), number of osteoblasts and osteoclasts, and the serum level of bone markers were compared on day 21.
RESULTS
RESULTS
The BV/TV ratio of the abiraterone, castration, and castration+abiraterone groups was lower than that of the control group. However, the change in the BV/TV ratio in the castration+abiraterone group was not significantly different from that in the castration group. There was no significant difference in the serum TRAP5b level and the number of osteoclasts and osteoblasts between the castration+abiraterone and the castration groups.
CONCLUSION
CONCLUSIONS
The addition of abiraterone to castration did not affect BMD in the murine model.
Identifiants
pubmed: 33144436
pii: 34/6/3291
doi: 10.21873/invivo.12167
pmc: PMC7811634
doi:
Substances chimiques
Androgen Antagonists
0
Androstenes
0
abiraterone
G819A456D0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3291-3299Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
J Androl. 2009 Jan-Feb;30(1):10-22
pubmed: 18641413
Lancet Oncol. 2019 Mar;20(3):408-419
pubmed: 30738780
J Urol. 2002 Jul;168(1):9-12
pubmed: 12050481
Eur J Cancer. 2017 Feb;72:54-61
pubmed: 28027516
Lancet. 1995 Jul 29;346(8970):265-9
pubmed: 7630245
Endocr Relat Cancer. 2014 Oct;21(5):769-81
pubmed: 25052474
J Androl. 2008 Mar-Apr;29(2):222-7
pubmed: 18077826
Ann Oncol. 2018 May 1;29(5):1235-1248
pubmed: 29529169
Cancer Lett. 2017 Jul 1;397:103-110
pubmed: 28373003
Ann Rheum Dis. 2016 Jun;75(6):952-7
pubmed: 26933146
Br J Cancer. 2004 Jun 14;90(12):2317-25
pubmed: 15150570
J Clin Oncol. 2008 Oct 1;26(28):4563-71
pubmed: 18645193
Bone. 2009 Oct;45(4):677-81
pubmed: 19501680
Life Sci. 1992;50(12):857-61
pubmed: 1312193
N Engl J Med. 2017 Jul 27;377(4):352-360
pubmed: 28578607
Bone. 2009 Oct;45(4):669-76
pubmed: 19539794
World J Urol. 2015 Aug;33(8):1079-85
pubmed: 25261259
Urology. 2007 Mar;69(3):500-4
pubmed: 17382153
Oncotarget. 2015 May 20;6(14):12520-8
pubmed: 25904051
Clin Cancer Res. 2017 Aug 1;23(15):4335-4346
pubmed: 28364014
Toxicol Sci. 2014 Mar;138(1):148-60
pubmed: 24284787
Eur Urol. 2015 Oct;68(4):570-7
pubmed: 25985882
N Engl J Med. 2015 Aug 20;373(8):737-46
pubmed: 26244877
J Clin Oncol. 2013 Aug 1;31(22):2791-8
pubmed: 23816964
Am J Pathol. 2018 Dec;188(12):2890-2901
pubmed: 30273606